دورية أكاديمية
Pharmacologic Management of Obesity after Liver Transplantation: A Critical Review.
| العنوان: | Pharmacologic Management of Obesity after Liver Transplantation: A Critical Review. |
|---|---|
| المؤلفون: | Zahrawi F; Section of Digestive Diseases, Yale School of Medicine, PO Box 208019, New Haven, CT 06520, USA., Fathma S; Waterbury Hospital, Yale New Haven Health, 64 Robbins St, Waterbury, CT 06708, USA., Mehal WZ; Section of Digestive Diseases, Yale School of Medicine, PO Box 208019, New Haven, CT 06520, USA., Banini BA; Section of Digestive Diseases, Yale School of Medicine, PO Box 208019, New Haven, CT 06520, USA. |
| المصدر: | Annals of gastroenterology and digestive disorders [Ann Gastroenterol Dig Disord] 2023; Vol. 6 (1), pp. 17-25. Date of Electronic Publication: 2023 Jun 07. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Somato Publications Country of Publication: United States NLM ID: 101744923 Publication Model: Print-Electronic Cited Medium: Internet NLM ISO Abbreviation: Ann Gastroenterol Dig Disord Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Middle town, Delaware : Somato Publications |
| مستخلص: | Post liver transplant obesity is associated with the development of metabolic disorders such as diabetes mellitus and nonalcoholic fatty liver disease and is a strong predictor of post-transplant mortality. Anti-obesity pharmacotherapy could serve as an effective adjunct to lifestyle modification in the post-transplant setting. Currently, utilization of anti-obesity medication in post liver transplant patients is limited by scarce data on their efficacy and safety in the post-transplant setting. Newer classes of anti-obesity medications, including the glucagon-like peptide 1 agonists (GLP-1) do not only help with weight loss but are effective anti-diabetic agents and are in further development for their potential hepatoprotective and renoprotective effects and reduction in cardiovascular risk. The objective of this manuscript was to critically review the efficacy and safety of anti-obesity pharmacotherapy in post-liver transplant patients. |
| References: | Med Princ Pract. 2022;31(3):254-261. (PMID: 35526530) Transplantation. 2019 Nov;103(11):2287-2303. (PMID: 31283679) Circulation. 2014 Jun 24;129(25 Suppl 2):S102-38. (PMID: 24222017) Am J Clin Nutr. 2021 Aug 2;114(2):824-825. (PMID: 34337661) Surg Endosc. 2013 Jan;27(1):81-5. (PMID: 22752278) Prog Transplant. 2022 Dec;32(4):357-362. (PMID: 36039519) JAMA. 2016 Jun 14;315(22):2424-34. (PMID: 27299618) Endocr Pract. 2016 Jul;22(7):842-84. (PMID: 27472012) Am Heart J. 2006 Mar;151(3):625-7. (PMID: 16504623) J Med Chem. 2015 Sep 24;58(18):7370-80. (PMID: 26308095) Am J Transplant. 2010 Jun;10(6):1420-7. (PMID: 20486907) Liver Transpl. 2020 Jan;26(1):141-159. (PMID: 31610081) Transplant Proc. 2020 Jan - Feb;52(1):276-283. (PMID: 31889539) Dig Dis Sci. 2015 Apr;60(4):1036-44. (PMID: 25596720) Transpl Int. 2006 Dec;19(12):1000-5. (PMID: 17081230) Ann Surg. 2008 Nov;248(5):863-70. (PMID: 18948816) Transl Gastroenterol Hepatol. 2020 Oct 05;5:51. (PMID: 33073046) Obes Surg. 2007 Nov;17(11):1517-9. (PMID: 18219781) Lancet. 2010 Aug 21;376(9741):595-605. (PMID: 20673995) Liver Transpl. 2016 May;22(5):644-55. (PMID: 26707008) Gastroenterol Hepatol. 2013 Oct;36(8):527-33. (PMID: 23731977) Liver Int. 2007 Feb;27(1):76-80. (PMID: 17241384) Transpl Int. 2005 Apr;18(4):461-6. (PMID: 15773968) Ann Pharmacother. 2013 Mar;47(3):340-9. (PMID: 23482732) Drugs R D. 2021 Jun;21(2):133-148. (PMID: 33772451) Hepatology. 2011 Aug;54(2):555-61. (PMID: 21567436) Ann Surg. 2023 Sep 1;278(3):e430-e439. (PMID: 36912445) Diabetes Obes Metab. 2019 Apr;21(4):1061-1065. (PMID: 30565376) Hepatology. 2017 Apr;65(4):1293-1305. (PMID: 27997989) Diabetes Obes Metab. 2020 May;22(5):879-884. (PMID: 31943645) Transplantation. 2016 Dec;100(12):2648-2655. (PMID: 27575690) Adv Ther. 2022 Jun;39(6):2452-2467. (PMID: 35503498) N Engl J Med. 2022 Jul 21;387(3):205-216. (PMID: 35658024) Liver Transpl. 2011 Nov;17 Suppl 3:S38-42. (PMID: 21761552) Liver Transpl. 2008 Nov;14(11):1648-54. (PMID: 18975273) Liver Transpl. 2010 Apr;16(4):431-9. (PMID: 20373454) Liver Int. 2018 Mar;38(3):553-563. (PMID: 28727287) Liver Transpl. 2013 Dec;19(12):1324-9. (PMID: 24039124) Diabetes Ther. 2020 Apr;11(4):987-994. (PMID: 32072430) Transplantation. 2010 May 15;89(9):1134-40. (PMID: 20386364) |
| معلومات مُعتمدة: | U54 AA027989 United States AA NIAAA NIH HHS |
| فهرسة مساهمة: | Keywords: Anti-obesity medication; GLP-1 agonists; Liver transplant; Obesity; Solid organ transplant; Weight loss |
| تواريخ الأحداث: | Date Created: 20231215 Latest Revision: 20231216 |
| رمز التحديث: | 20231216 |
| مُعرف محوري في PubMed: | PMC10719957 |
| PMID: | 38098758 |
| قاعدة البيانات: | MEDLINE |
| الوصف غير متاح. |